Unassociated Document Company Contact: Investor Relations Contact : Senesco Technologies, Inc. FD Jack Van Hulst Brian Ritchie Chief Executive Officer ( brian.ritchie@fd.com ) ( jvanhulst@senesco.com ) (212) 850-5600 (73

SENESCO INSIDERS PURCHASE SENESCO SECURITIES HELD

STANFORD VENTURE CAPITAL HOLDINGS

BRUNSWICK, N.J. - February 22, 2010 - Senesco Technologies, Inc. ("Senesco"

or the "Company") (NYSE Amex US: SNT) reported today that

certain insiders of Senesco Technologies, Inc., a Delaware corporation,

purchased all of the convertible debentures, warrants and common stock of the

Company which are held by Stanford Venture Capital Holdings, Inc.

closing of this transaction fortifies our shareholder base, and should enable us

to more easily attract suitable financing," said Harlan Waksal, M.D., Senesco's

Chairman of the Board. "This agreement is also representative of the

significant confidence the Board has in the Company's prospects."

Senesco Technologies, Inc.

Technologies, Inc. is a U.S. biotechnology company, headquartered in New

Brunswick, NJ. Senesco has initiated preclinical research to trigger or delay

cell death in mammals (apoptosis) to determine if the technology is applicable

in human medicine. Accelerating apoptosis may have applications to development

of cancer treatments. Delaying apoptosis may have applications to certain

inflammatory and ischemic diseases. Senesco takes its name from the scientific

term for the aging of plant cells: senescence. Delaying cell breakdown in plants

extends freshness after harvesting, while increasing crop yields, plant size and

resistance to environmental stress. The Company believes that its technology can

be used to develop superior strains of crops without any modification other than

delaying natural plant senescence. Senesco has partnered with leading-edge

companies engaged in agricultural biotechnology and earns research and

development fees for applying its gene-regulating platform technology to enhance

its partners' products. Certain statements included in this

press release are forward-looking statements within the meaning of the Private

Securities Litigation Reform Act of 1995. Actual results could differ materially

from such statements expressed or implied herein as a result of a variety of

factors, including, but not limited to: the ability of the Company to consummate

additional financings; the development of the Company's gene technology; the

approval of the Company's patent applications; the successful implementation of

the Company's research and development programs and joint ventures; the success

of the Company's license agreements; the successful conversion of the Company's

letter of intent into a license agreement; the acceptance by the market of the

Company's products; success of the Company's preliminary studies and preclinical

research; competition and the timing of projects and trends in future operating

performance, as well as other factors expressed from time to time in the

Company's periodic filings with the Securities and Exchange Commission (the

"SEC"). As a result, this press release should be read in conjunction with the

Company's periodic filings with the SEC. The forward-looking statements

contained herein are made only as of the date of this press release, and the

Company undertakes no obligation to publicly update such forward-looking

statements to reflect subsequent events or circumstances.